Metraipolis › archive › dc_22fe2ba73722

Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management — Europe PMC PMID:42309786

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42309786
DOI
10.1111/1759-7714.70328
License (as archived)
solo-consultazione
Archived
2026-11-01T01:34:03.556Z
SHA-256 of the archived text
a86ab10ae744cdea69597c70d954bb71b5e5546e9db78e703fcb569b78c6394c
Stable URL of this page
https://metraipolis.com/documento/dc_22fe2ba73722

How to cite

Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management — Europe PMC PMID:42309786 — Europe PMC (en), https://europepmc.org/article/MED/42309786 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_22fe2ba73722 (Metraipolis archive dc_22fe2ba73722, sha256 a86ab10ae744cdea69597c70d954bb71b5e5546e9db78e703fcb569b78c6394c)
BibTeX
@misc{dc22fe2ba73722,
  title = {Association Between Osimertinib Dose Reduction and Treatment Outcomes in First-Line EGFR-Mutated Advanced NSCLC: The Impact of Post-Progression Management — Europe PMC PMID:42309786},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42309786},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_22fe2ba73722; sha256 a86ab10ae744cdea69597c70d954bb71b5e5546e9db78e703fcb569b78c6394c},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42309786. Agents can read the archived copy with the MCP tool read_document.